Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy

Manhal Izzy, Ghalib Jibara, Aws Aljanabi, Mustafa Alani, Emily Giannattasio, Hina Zaidi, Zaid Said, Paul Gaglio, Allan W. Wolkoff, John F. Reinus

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Individuals ineligible for interferon-based hepatitis C therapy may have a worse prognosis than patients who have failed or not received treatment. Aims: To provide information about the limitations of medical treatment of hepatitis C in real-world patients. Methods: We studied 969 treatment-ineligible patients and 403 treated patients enrolled between 1/1/01 and 6/30/06; data were collected until 3/31/13. Treatment barriers were grouped into five categories and classified as health-related or health-unrelated. Fibrosis stage was assessed initially and at the end of follow-up. Mortality was determined by search of the Social Security database. Death certificates of treatment-ineligible patients were reviewed. Results: Initially, 288 individuals had advanced fibrosis and compensated disease; 87 untreated patients developed advanced fibrosis during follow-up. Health-related treatment barriers were more commonly associated with fibrosis progression and worse survival. During follow-up, 247 untreated patients died: 47% of liver-related and 53% of liver-unrelated causes. Patients with significant comorbid illness had the worst five-year (70%) and ten-year (50.5%) survival. Despite high mortality (47%) in persons with decompensated liver disease, no treatment barrier was associated with a greater incidence of liver-related death. Only significant comorbid medical illness was an independent predictor of disease progression; however, it was not associated with a greater incidence of liver-related death. Furthermore, treated patients had better 10-year survival than untreated patients on Kaplan-Meier analysis (80.3% vs. 74.5%, P = 0.005). Conclusion: Many patients with hepatitis C will die of non-liver-related causes and may not be helped by anti-viral treatment.

Original languageEnglish (US)
JournalJournal of Clinical and Experimental Hepatology
DOIs
StateAccepted/In press - Jan 17 2016

Fingerprint

Hepatitis C
Interferons
Fibrosis
Mortality
Therapeutics
Liver
Survival
Health
Death Certificates
Social Security
Incidence
Kaplan-Meier Estimate
Disease Progression
Liver Diseases
Databases

Keywords

  • Hepatitis C
  • Liver fibrosis
  • Mortality
  • Progression
  • Treatment barrier

ASJC Scopus subject areas

  • Hepatology

Cite this

Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy. / Izzy, Manhal; Jibara, Ghalib; Aljanabi, Aws; Alani, Mustafa; Giannattasio, Emily; Zaidi, Hina; Said, Zaid; Gaglio, Paul; Wolkoff, Allan W.; Reinus, John F.

In: Journal of Clinical and Experimental Hepatology, 17.01.2016.

Research output: Contribution to journalArticle

Izzy, Manhal ; Jibara, Ghalib ; Aljanabi, Aws ; Alani, Mustafa ; Giannattasio, Emily ; Zaidi, Hina ; Said, Zaid ; Gaglio, Paul ; Wolkoff, Allan W. ; Reinus, John F. / Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy. In: Journal of Clinical and Experimental Hepatology. 2016.
@article{48371778158b42a293cd6f765085ea92,
title = "Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy",
abstract = "Background: Individuals ineligible for interferon-based hepatitis C therapy may have a worse prognosis than patients who have failed or not received treatment. Aims: To provide information about the limitations of medical treatment of hepatitis C in real-world patients. Methods: We studied 969 treatment-ineligible patients and 403 treated patients enrolled between 1/1/01 and 6/30/06; data were collected until 3/31/13. Treatment barriers were grouped into five categories and classified as health-related or health-unrelated. Fibrosis stage was assessed initially and at the end of follow-up. Mortality was determined by search of the Social Security database. Death certificates of treatment-ineligible patients were reviewed. Results: Initially, 288 individuals had advanced fibrosis and compensated disease; 87 untreated patients developed advanced fibrosis during follow-up. Health-related treatment barriers were more commonly associated with fibrosis progression and worse survival. During follow-up, 247 untreated patients died: 47{\%} of liver-related and 53{\%} of liver-unrelated causes. Patients with significant comorbid illness had the worst five-year (70{\%}) and ten-year (50.5{\%}) survival. Despite high mortality (47{\%}) in persons with decompensated liver disease, no treatment barrier was associated with a greater incidence of liver-related death. Only significant comorbid medical illness was an independent predictor of disease progression; however, it was not associated with a greater incidence of liver-related death. Furthermore, treated patients had better 10-year survival than untreated patients on Kaplan-Meier analysis (80.3{\%} vs. 74.5{\%}, P = 0.005). Conclusion: Many patients with hepatitis C will die of non-liver-related causes and may not be helped by anti-viral treatment.",
keywords = "Hepatitis C, Liver fibrosis, Mortality, Progression, Treatment barrier",
author = "Manhal Izzy and Ghalib Jibara and Aws Aljanabi and Mustafa Alani and Emily Giannattasio and Hina Zaidi and Zaid Said and Paul Gaglio and Wolkoff, {Allan W.} and Reinus, {John F.}",
year = "2016",
month = "1",
day = "17",
doi = "10.1016/j.jceh.2016.02.006",
language = "English (US)",
journal = "Journal of Clinical and Experimental Hepatology",
issn = "0973-6883",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy

AU - Izzy, Manhal

AU - Jibara, Ghalib

AU - Aljanabi, Aws

AU - Alani, Mustafa

AU - Giannattasio, Emily

AU - Zaidi, Hina

AU - Said, Zaid

AU - Gaglio, Paul

AU - Wolkoff, Allan W.

AU - Reinus, John F.

PY - 2016/1/17

Y1 - 2016/1/17

N2 - Background: Individuals ineligible for interferon-based hepatitis C therapy may have a worse prognosis than patients who have failed or not received treatment. Aims: To provide information about the limitations of medical treatment of hepatitis C in real-world patients. Methods: We studied 969 treatment-ineligible patients and 403 treated patients enrolled between 1/1/01 and 6/30/06; data were collected until 3/31/13. Treatment barriers were grouped into five categories and classified as health-related or health-unrelated. Fibrosis stage was assessed initially and at the end of follow-up. Mortality was determined by search of the Social Security database. Death certificates of treatment-ineligible patients were reviewed. Results: Initially, 288 individuals had advanced fibrosis and compensated disease; 87 untreated patients developed advanced fibrosis during follow-up. Health-related treatment barriers were more commonly associated with fibrosis progression and worse survival. During follow-up, 247 untreated patients died: 47% of liver-related and 53% of liver-unrelated causes. Patients with significant comorbid illness had the worst five-year (70%) and ten-year (50.5%) survival. Despite high mortality (47%) in persons with decompensated liver disease, no treatment barrier was associated with a greater incidence of liver-related death. Only significant comorbid medical illness was an independent predictor of disease progression; however, it was not associated with a greater incidence of liver-related death. Furthermore, treated patients had better 10-year survival than untreated patients on Kaplan-Meier analysis (80.3% vs. 74.5%, P = 0.005). Conclusion: Many patients with hepatitis C will die of non-liver-related causes and may not be helped by anti-viral treatment.

AB - Background: Individuals ineligible for interferon-based hepatitis C therapy may have a worse prognosis than patients who have failed or not received treatment. Aims: To provide information about the limitations of medical treatment of hepatitis C in real-world patients. Methods: We studied 969 treatment-ineligible patients and 403 treated patients enrolled between 1/1/01 and 6/30/06; data were collected until 3/31/13. Treatment barriers were grouped into five categories and classified as health-related or health-unrelated. Fibrosis stage was assessed initially and at the end of follow-up. Mortality was determined by search of the Social Security database. Death certificates of treatment-ineligible patients were reviewed. Results: Initially, 288 individuals had advanced fibrosis and compensated disease; 87 untreated patients developed advanced fibrosis during follow-up. Health-related treatment barriers were more commonly associated with fibrosis progression and worse survival. During follow-up, 247 untreated patients died: 47% of liver-related and 53% of liver-unrelated causes. Patients with significant comorbid illness had the worst five-year (70%) and ten-year (50.5%) survival. Despite high mortality (47%) in persons with decompensated liver disease, no treatment barrier was associated with a greater incidence of liver-related death. Only significant comorbid medical illness was an independent predictor of disease progression; however, it was not associated with a greater incidence of liver-related death. Furthermore, treated patients had better 10-year survival than untreated patients on Kaplan-Meier analysis (80.3% vs. 74.5%, P = 0.005). Conclusion: Many patients with hepatitis C will die of non-liver-related causes and may not be helped by anti-viral treatment.

KW - Hepatitis C

KW - Liver fibrosis

KW - Mortality

KW - Progression

KW - Treatment barrier

UR - http://www.scopus.com/inward/record.url?scp=84961841588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961841588&partnerID=8YFLogxK

U2 - 10.1016/j.jceh.2016.02.006

DO - 10.1016/j.jceh.2016.02.006

M3 - Article

AN - SCOPUS:84961841588

JO - Journal of Clinical and Experimental Hepatology

JF - Journal of Clinical and Experimental Hepatology

SN - 0973-6883

ER -